RecruitingNot ApplicableNCT06718894

Multitarget Strategy for Primary Podocytopathies


Sponsor

Fondazione IRCCS Ca' Granda, Ospedale Maggiore Policlinico

Enrollment

150 participants

Start Date

Jun 19, 2025

Study Type

INTERVENTIONAL

Conditions

Summary

The goal of this clinical trial is to verify whether a cell culture system can be used to evaluate the presence of a factor capable of causing proteinuria in the serum of patients with primary podocytopathies. This system will also be used to evaluate the in vitro efficacy of a combined therapy for the treatment of this disorder. Researchers will compare samples from patients with primary podocytopathies with those obtained from healthy subjects and patients with other renal disorders. Participants will be asked to visit the clinic at regular intervals for up to 36 months, and to provide blood and urine samples (and a sample of the discarded plasmapheresis effluent in case the procedure is performed).


Eligibility

Inclusion Criteria8

  • Signature of informed consent for study participation
  • One of the following conditions:
  • Patients with primary podocytopathies (with a histological diagnosis of FSGS or MCD) showing clinical and/or histological evidence of post-transplant recurrence.
  • Patients with primary podocytopathies (with a histological diagnosis of FSGS or MCD) without clinical and/or histological evidence of post-transplant recurrence.
  • Patients with primary podocytopathies in their native kidneys in an active clinical phase of the disease.
  • Patients with podocytopathies presenting clinical features compatible with a secondary form due to another condition.
  • Patients with glomerulonephritis other than primary podocytopathies (e.g., IgA nephropathy, systemic lupus erythematosus, membranous nephropathy).
  • Patients with no history of renal diseases

Exclusion Criteria3

  • Subjects affected by primary podocytopathies or other glomerulonephritides in clinical remission or with ESRD (eGFR \< 15 ml/min) and/or on renal replacement therapy
  • Individuals unable to understand and consent to the study procedures
  • Any clinical condition that, according to the investigator's judgment, could compromise patient safety during study participation

Interested in this trial?

Get notified about updates and connect with the research team.

Interventions

OTHERBiologic fluid sampling

The only interventions in addition to standard clinical practice will be blood sampling, the collection of morning spot urine and the collection of the discarded effluent of the plasmapheresis procedure (when performed according to clinical indication).


Locations(2)

Fondazione IRCCS Ca' Granda Ospedale Maggiore Policlinico

Milan, Italy

Fondazione IRCCS Policlinico San Matteo

Pavia, Italy

View Full Details on ClinicalTrials.gov

For the most up-to-date information, visit the official listing.

Visit

NCT06718894


Related Trials